Literature DB >> 779634

Reevaluation of kanamycin dosage in infants and children.

J P Hieber, J D Nelson.   

Abstract

It was recently reported that the dosage of kanamycin formerly recommended for neonates of 7.5 mg/kg every 12 h did not produce therapeutic serum concentrations of 15 to 25 mug/ml, but a larger dosage of 10 mg/kg every 12 h was required. Reevaluation of the pharmacokinetics of kanamycin in infants and children was therefore undertaken. Sixteen time-concentration curves after a dose of 5 mg/kg were obtained from patients 2 months to 12 years of age; the mean peak serum kanamycin concentration was 10.9 (range, 3.6 to 17.9) mug/ml at 0.5 h. Ten time-concentration curves were obtained after a dose of 10 mg/kg; the mean peak serum concentration was 17.6 (range, 8.4 to 30) mug/ml. Eight patients were studied on successive days, and there was doubling of the 1-h peak serum concentration when the dose of kanamycin was increased from 5 to 10 mg/kg. Standard serum bactericidal tests were done against Escherichia coli and Enterobacter cloacae strains, each with a minimal bactericidal concentration of 5 mug of kanamycin per ml. All 3 sera containing 21 mug or more of kanamycin per ml demonstrated a bactericidal titer, whereas only 2 of 23 sera containing less than 21 mug of kanamycin per ml did so. The currently recommended dosage of kanamycin for infants and children fails to produce serum concentrations in the therapeutic range, and preliminary data suggest that the dosage should be increased to 10 mg/kg per dose every 8 h.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 779634      PMCID: PMC429647          DOI: 10.1128/AAC.9.6.899

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Changing pattern of the antimicrobial susceptibilities of Escherichia coli in neonatal infections.

Authors:  G H McCracken
Journal:  J Pediatr       Date:  1971-06       Impact factor: 4.406

2.  Pharmacokinetics of accumulation.

Authors:  J M van Rossum
Journal:  J Pharm Sci       Date:  1968-12       Impact factor: 3.534

3.  Clinical pharmacology of kanamycin in premature infants.

Authors:  H J Simon; S G Axline
Journal:  Ann N Y Acad Sci       Date:  1966-06-14       Impact factor: 5.691

4.  Reappraisal of kanamycin usage in neonates.

Authors:  J B Howard; G H McCracken
Journal:  J Pediatr       Date:  1975-06       Impact factor: 4.406

5.  The ototoxic effects of kanamycin sulfate in infants and children.

Authors:  M D YOW; N E TENGG; J BANGS; T BANGS; W STEPHENSON
Journal:  J Pediatr       Date:  1962-02       Impact factor: 4.406

6.  Microbioassay of antimicrobial agents.

Authors:  H J Simon; E J Yin
Journal:  Appl Microbiol       Date:  1970-04

7.  Kanamycin serum levels in infants and children.

Authors:  S H BERGER; P F WEHRLE
Journal:  Ann N Y Acad Sci       Date:  1958-09-30       Impact factor: 5.691

8.  Kanamycin in the treatment of infections in infants and children.

Authors:  R H HIGH; A SARRIA; N N HUANG
Journal:  Ann N Y Acad Sci       Date:  1958-09-30       Impact factor: 5.691

  8 in total
  2 in total

1.  Variability and predictability of the plasma concentration of ampicillin and kanamycin in new-born infants.

Authors:  O M Driessen; N Sorgedrager; M F Michel; K F Kerrebijn; J Hermans
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

Review 2.  Bioanalysis of aminoglycosides using high-performance liquid chromatography.

Authors:  Seth K Amponsah; Joseph A Boadu; Daniel K Dwamena; Kwabena F M Opuni
Journal:  ADMET DMPK       Date:  2022-02-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.